Combined targeted therapy and immunotherapy in the treatment of advanced melanoma

Recently, a CTLA-4 antibody and BRAF inhibitors showed survival benefits in advance melanoma treatment. The documentation of immune infiltrates in melanomas early during BRAF inhibitor therapy provides a scientific rationale for combination therapy with both treatments with possible synergistic bene...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilmott, James S., Scolyer, Richard A., Long, Georgina V., Hersey, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2012
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3489773/
https://www.ncbi.nlm.nih.gov/pubmed/23189245
http://dx.doi.org/10.4161/onci.19865
Descripción
Sumario:Recently, a CTLA-4 antibody and BRAF inhibitors showed survival benefits in advance melanoma treatment. The documentation of immune infiltrates in melanomas early during BRAF inhibitor therapy provides a scientific rationale for combination therapy with both treatments with possible synergistic benefits. This commentary reviews immune responses induced by BRAF inhibitors.

Ejemplares similares